The Glycoimmunology research lab employs unique molecular and biological methods combined with patient-centric approaches to disentangle biological mechanisms modulated by glycosylation and novel glycan-based therapies.
Our particular focus has been on sialylated glycans that affect the function of relevant cell surface molecules. We developed technologies to alter sialic acid contents and a multi-modular platform for high-throughput development of anti-glycan antibodies, with potential clinical application.
We collaborate extensively with pharmaceuticals and patient associations to translate into therapies for cancer and congenital disorders of glycosylation (CDG).
Understanding the role of sialic acid containing glycans in cancer and congenital disorders of glycosylation to identify new therapeutic strategies
Our seminal studies identified relevant glycans biomarkers in cancer which fueled the interest in clinics. We developed antisialyl Tn antibodies that selectively target cancer cells and reduce tumour burden in preclinical settings. They are now being explored by CellmAbs pharmaceutical as immune oncology agents.
Our observations that sialic acid modulates the potency of dendritic cells and MHC-I turnover pinpointed new disease mechanisms and paved the development of innovative therapies. It also
pinpointed affected immune pathways and ways for their therapeutic modulation.
Currently, we lead an unique patient-centric network, the CDG-Allies PPAIN to empower CDG community and improve their quality of life.
- “GenMedcare therapeutics research agreement”, Total and Unit funding: €50,000, Paula Videira (PI).
- “Siamab therapeutics research agreement”, Total and Unit funding: €20,000, Paula Videira (PI).
- “GlyCoCan - exploiting glycosylation of colorectal cancer for the development of improved diagnostics and therapeutics”, Total funding: €3,2M and Unit funding: €476,712, Paula Videira (Collaborator).
- “Trifunctional antibodies and dendritic cell-based technologies: a combined approach to cancer immunotherapy” Bluepharma | University of Coimbra Award, Total and Unit funding: €20,000, Paula Videira (PI).
- “ADVANCE - desenvolvimento de novas vacinas anti- cancro a partir de células dendríticas”, FEDER,-QREN, Total funding: €431,012, Unit funding: €215,506 , Paula Videira (co-PI).
Deschepper, FM; Zoppi, R; Pirro, M; Hensbergen, PJ; Dall'Olio, F; Kotsias, M; Gardner, RA; Spencer, DIR; Videira, PA. 2020. L1CAM as an E-selectin Ligand in Colon Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21, DOI: 10.3390/ijms21218286
Loureiro, LR; Feldmann, A; Bergmann, R; Koristka, S; Berndt, N; Mathe, D; Hegedus, N; Szigeti, K; Videira, PA; Bachmann, M; Arndt, C. 2020. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 39, DOI: 10.1186/s13046-020-01572-4
Francisco, R; Pascoal, C; Marques-da-Silva, D; Brasil, S; Pimentel-Santos, FM; Altassan, R; Jaeken, J; Grosso, AR; Ferreira, VD; Videira, PA. 2020. New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach. Journal of Clinical Sleep Medicine, 9, DOI: 10.3390/jcm9072092
Altassan, R; Radenkovic, S; Edmondson, AC; Barone, R; Brasil, S; Cechova, A; Coman, D; Donoghue, S; Falkenstein, K; Ferreira, V; Ferreira, C; Fiumara, A; Francisco, R; Freeze, H; Grunewald, S; Honzik, T; Jaeken, J; Krasnewich, D; Lam, C; Lee, J; Lefeber, D; Marques-da-Silva, D; Pascoal, C; Quelhas, D; Raymond, KM; Rymen, D; Seroczynska, M; Serrano, M; Sykut-Cegielska, J; Thiel, C; Tort, F; Vals, MA; Videira, P; Voermans, N; Witters, P; Morava, E. 2020. International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management. JOURNAL OF INHERITED METABOLIC DISEASE, DOI: 10.1002/jimd.12286
K. Rengasamy, H. Khan, S. Gowrishankar, R. Lagoa, F. Mahoomodally, et al.. 2019. The role of flavonoids in autoimmune diseases: therapeutic updates. PHARMACOLOGY & THERAPEUTICS, 194, DOI: 10.1016/j.pharmthera.2018.09.009